SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $6.5 billion biotech company with exceptional financial health according to InvestingPro metrics, announced today that argenx has received ...

"We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Argenx gains EU approval for VYVGART subcutaneous injection, enhancing treatment options for autoimmune diseases.

VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional.

There are a few different delivery systems—IVs, subcutaneous injections, nasal sprays, and of course, the best NAD+ supplements—to help address everything from loss of muscle mass to brain fog ...

To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and ...

WICHITA, Kan., May 29, 2025 /PRNewswire/ -- Angels for Change today announced that Fagron Sterile Services US (FSS) has been awarded a 2025 Project PROTECT grant to produce sterile water for ...

The subcutaneous injection is a tyrosine kinase inhibitor designed to block all forms of VEGF, Singer explained at the Retina World Congress.

A subcutaneous injectable form of nivolumab is available to treat melanoma, non-small cell lung cancer, renal cell cancer, and many other cancers.

No patients discontinued treatment because of these AEs. None of the participants reported pain at the injection site; there were no subsequent complications—including redness, erythema, or abscess ...